Read Zacks_Analysts' blog in RSS
June 21, 2010
Share This
Massachusetts-based medical device maker ZOLL Medical Corp (ZOLL) won a major supply contract for its external defibrillators, which are devices that diagnose and treat sudden cardiac arrest (SCA). The company has been selected by U.K's heart charity “British Heart Foundation" (BHF) as the supplier of automated external defibrillators (AEDs).
ZOLL Medical designs, manufactures, markets and sells non-invasive resuscitation (an emergency life-support procedure) devices and related software solutions both in the U.S. and overseas markets. The company’s solutions include defibrillation devices such as the M Series, E Series, R Series, AED Plus, AED Pro, and LifeVest Wearable Defibrillator.
ZOLL is a leading player in the global market for external defibrillators, which is worth more than $1 billion. The company is the innovator of a wide range of product features that have become the standard of care in the external defibrillator industry. ZOLL remains committed to expanding its product range to sustain growth in this market. The company competes with Cardiac Science Corporation (CSCX), HeartSine Technologies, and Defibtech in the AED market.
ZOLL is expanding its presence in the international markets, representing a major impetus for growth. The company conducts its international operations through its subsidiaries in Canada, Germany, Austria, The Netherlands, France, Australia, New Zealand and the U.K. International markets contributed roughly 25% of consolidated revenues for fiscal 2009.
SCA, an abrupt loss of cardiac function, is one of the major causes of unexpected deaths, claiming roughly 200,000 lives annually in the U.K. Early defibrillation raises the chance of survival from just 5% to more than 50%. As such, availability of AEDs within the first few minutes of the onset of SCA may considerably improve survival rates. With the BHF contract in place, ZOLL is expected to play a major role in treating this near-fatal condition in the U.K.
Read the full analyst report on "ZOLL"
Read the full analyst report on "CSCX"
Zacks Investment Research